OncoArendi Therapeutics (OAT) is an innovative biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics for neoplastic and inflammatory diseases.
OncoArendi's business model is strictly focused on drug discovery and development, with its core strength in high quality medicinal chemistry and preclinical biology, enhanced by scientific collaborations with the key opinion leaders in specific disease areas and prudent use of CROs.
OncoArendi Therapeutics was incepted in 2012. Following the Founders seed and in-kind contributions, OncoArendi Therapeutics closed an Angel and two investment rounds totalling about 34 million PLN (9 million USD, based on averaged variable exchange rate over time).
In addition OncoArendi has been able to significantly leverage the private capital raised with non-dilutive grants, with total funding exceeding 100 million PLN (almost 30 million USD, based on averaged variable exchange rate over time).
The total cumulative (private and public) funding should allow OncoArendi Therapeutics to progress four of its ongoing programs up to Phase II clinical trials and fill its pipeline with new, early stage exploratory programs.